INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in INSMED Inc. On April 16, 2026, he exercised options for 10,699 shares of Common Stock at exercise prices of $30.46 and $17.16 per share.
That same day he sold a total of 10,699 shares of Common Stock in open-market transactions at weighted average prices between $142.39 and $146.02 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions he directly held 301,185 shares, with an additional 233,924 shares held indirectly by a trust.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,699 shares ($1,540,332)
Net Sell
9 txns
Insider
Lewis William
Role
Chair and CEO
Sold
10,699 shs ($1.54M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 6,259 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 4,440 | $0.00 | -- |
| Exercise | Common Stock | 6,259 | $30.46 | $191K |
| Exercise | Common Stock | 4,440 | $17.16 | $76K |
| Sale | Common Stock | 2,246 | $142.99 | $321K |
| Sale | Common Stock | 5,373 | $143.81 | $773K |
| Sale | Common Stock | 2,255 | $144.66 | $326K |
| Sale | Common Stock | 825 | $145.79 | $120K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 37,555 shares (Direct);
Common Stock — 307,444 shares (Direct);
Common Stock — 233,924 shares (Indirect, By trust)
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 2,246 shares sold at prices ranging from $142.39 to $143.38 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 5,373 shares sold at prices ranging from $143.39 to $144.32 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 2,255 shares sold at prices ranging from $144.40 to $145.20 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 825 shares sold at prices ranging from $145.53 to $146.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Key Figures
Options exercised: 10,699 shares
Exercise prices: $30.46 and $17.16 per share
Shares sold: 10,699 shares
+5 more
8 metrics
Options exercised
10,699 shares
Stock option exercises on April 16, 2026
Exercise prices
$30.46 and $17.16 per share
Strike prices of exercised stock options
Shares sold
10,699 shares
Open-market sales on April 16, 2026
Sale prices
$142.39–$146.02 per share
Weighted average sales price ranges from footnotes
Direct holdings after
301,185 shares
Common stock directly owned after transactions
Indirect holdings after
233,924 shares
Common stock held indirectly by trust
Net buy/sell direction
Net sell of 10,699 shares
Form 4 transaction summary
10b5-1 plan adoption date
September 4, 2025
Footnote describing pre-arranged trading plan
Key Terms
Rule 10b5-1 trading plan, Stock Option (right to buy), weighted average sales price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
weighted average sales price financial
"This is the weighted average sales price representing 2,246 shares sold at prices ranging"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting schedule financial
"The options became exercisable based on the following vesting schedule: 25% vested"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
FAQ
What did INSMED (INSM) CEO William Lewis do in this Form 4 filing?
William Lewis exercised stock options and sold shares of INSMED common stock. He exercised options for 10,699 shares, then sold 10,699 shares in open-market transactions while remaining a significant shareholder after the trades.
What stock options did the INSMED (INSM) CEO exercise in this filing?
He exercised stock options covering 10,699 shares of INSMED common stock. The exercise prices were $30.46 and $17.16 per share, converting previously granted options into common shares before the reported open-market sales.
Were the INSMED (INSM) CEO’s stock sales made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. Such plans are pre-arranged programs that schedule trades in advance under SEC rules.